[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-350551-105":59,"doc-detail-350551-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","outcomes-for-patients-with-micro-invasive-or-small-her2-breast-cancer-in-northern-sydney-local-health-district","Outcomes for Patients With Micro-Invasive or Small HER2+ Breast Cancer in Northern Sydney Local Health District","","This single-center retrospective study reviews outcomes for patients with microinvasive and small HER2+ node-negative breast cancer in Northern Sydney Local Health District. Patients with HER2+, pT1mic-bN0M0 disease treated with surgery between 2006 and 2022 were analyzed. Primary endpoint was invasive disease-free survival; secondary endpoint was overall survival. Findings show favorable 5-year iDFS and OS, with higher grades and Ki-67 in the pT1b group and trastuzumab use linked to larger size and higher histologic grade.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/outcomes-for-patients-with-micro-invasive-or-small-her2-breast-cancer-in-northern-sydney-local-health-district/350551/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/outcomes-for-patients-with-micro-invasive-or-small-her2-breast-cancer-in-northern-sydney-local-health-district/350551.png","ImageObject",300,407,{"name":92,"@type":93},"Mary Man","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the primary outcome of the study?","Question",{"text":112,"@type":113},"The primary outcome was invasive disease-free survival (iDFS).","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Who were the study participants?",{"text":117,"@type":113},"Patients with HER2+ pT1mic-bN0M0 disease who underwent surgery in Northern Sydney Local Health District between 2006 and 2022 were included.",{"name":119,"@type":110,"acceptedAnswer":120},"How did outcomes compare between pT1mic/a and pT1b groups?",{"text":121,"@type":113},"The 5-year iDFS and OS were 93% for the pT1mic/a group and 100% for the pT1b group, with p = 0.29 reported.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},350551,1790828800,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},7421720224475,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Asia-Pacific Journal of  \nClinical Oncology  \nORIGINAL ARTICLE   \nOutcomes for Patients With Micro-Invasive or Small HER2+ Breast Cancer in Northern Sydney Local Health District  \nYuanyuan Xue1  Katrina Moore2  Tricia Saurine3  David Chan4  Lina Pugliano4  Connie Diakos1, 4   \n1Northern Clinical School, The University of Sydney, Camperdown, New South Wales, Australia  2 Department of Breast Surgery, Royal North Shore Hospital, St Leonards, New South Wales, Australia  3 Department of Anatomical Pathology, New South Wales Health Pathology, Royal North Shore Hospital, St Leonards, New South Wales, Australia  4 Department of Medical Oncology, Northern Sydney Cancer Centre, Royal North Shore Hospital, St Leonards, New South Wales, Australia  \nCorrespondence: Connie Diakos ([connie.diakos@sydney.edu.au](connie.diakos@sydney.edu.au))  \nReceived: 18 May 2025  Accepted: 17 January 2026  \nKeywords: HER2+ | recurrence | prognosis | small breast cancer | trastuzumab  \nABSTRACT  \nAim: This study aimed to review the outcomes for patients with microinvasive and small HER2+ breast cancers, compare the clinicopathological features, and explore the patterns of care.  \nMethods: In this single-center retrospective study, patients with HER2+, pT1mic-bN0M0 disease who underwent surgery in Northern Sydney Local Health District between 2006 and 2022 were selected. The primary outcome was invasive disease-free survival (iDFS), and secondary outcome was overall survival (OS) .  \nResults: Of the 32 eligible patients, those with pT1b disease had higher histological grades and Ki-67 indices, with a higher rate of trastuzumab administration. One recurrence and one death were observed in the pT1a group. The 5-year iDFS and OS were 93% for the pT1mic/a group and 100% for the pT1b group (p = 0.29) . Sixty-six percent of patients received adjuvant trastuzumab. Trastuzumab prescription was associated with larger tumor sizes (p = 0.008) and higher histologic grades (p = 0.023) . Conclusions: Patients with microinvasive or small HER2+ node-negative breast cancer experience favorable outcomes. The pT1b group had higher histological grades and proliferative indices. Patients with pT1b disease or higher tumor grades were more likely to receive trastuzumab. While trastuzumab is recommended for pT1b disease with strong evidence, its use in pT1a disease should be balanced against its unclear benefits and known toxicities.  \n1  Introduction  \nSmall breast carcinomas are increasingly seen by clinicians due to the widespread adoption of breast screening and improvements in screening techniques [1] .  \nPrevious studies have revealed a favorable long-term prognosis for patients with small breast cancers [2, 3] . However, HER2-positivity (HER2+) is associated with an increased risk of recur-  \nrence and reduced survival in patients with small node-negative tumors [4–10] .  \nTrastuzumab has been shown to be effective in improving outcomes for HER2+ breast cancer, based on evidence from several large clinical trials, including NSABP B31, NCCTG N9831, and HERA [11–13] . However, these trials excluded patients with tumors smaller than 10 mm without lymph node involvement. The NCCN guidelines [14] recommend treatment with  \nThis is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.  \n© 2026 The Author(s). Asia-Pacific Journal of Clinical Oncology published by John Wiley & Sons Australia, Ltd.  \nAsia-Pacific Journal of Clinical Oncology, 2026; 22:564–572 564 of 572  \n[https://doi.org/10.1111/ajco.70100](https://doi.org/10.1111/ajco.70100)  \ntrastuzumab for tumors larger than 6 mm, but for tumors smaller than 6 mm, there are no clear recommendations from National Guideline Committees, due to limited available evidence.  \nEmerging data on outcomes for patients wi","cbCaigKujYdGE8LK","https://ap.wps.com/l/cbCaigKujYdGE8LK","pdf",672997,"English","# Abstract\n## Aim\n## Methods\n## Results\n## Conclusions\n# Introduction\n# Materials and Methods\n## Study Design\n## Participants","[{\"question\":\"What was the primary outcome of the study?\",\"answer\":\"The primary outcome was invasive disease-free survival (iDFS).\"},{\"question\":\"Who were the study participants?\",\"answer\":\"Patients with HER2+ pT1mic-bN0M0 disease who underwent surgery in Northern Sydney Local Health District between 2006 and 2022 were included.\"},{\"question\":\"How did outcomes compare between pT1mic/a and pT1b groups?\",\"answer\":\"The 5-year iDFS and OS were 93% for the pT1mic/a group and 100% for the pT1b group, with p = 0.29 reported.\"}]","Outcomes for Patients With Micro-Invasive or Small HER2+ Breast Cancer in Northern Sydney Local Health District | PDF",1790089555,23,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fda4747fae4b913ede142669f702ecd6.webp",983,1283,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/99dd7f72378b15b380e76dffba50081b.webp",982,1281,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/49c4779e84501e955e29b15816e9068e.webp",981,1280,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1775979cbcd68c16d236c0e99e8532c9.webp",980,1279]